Preimplantation Genetic Testing Market: Current Analysis and Forecast (2021-2027)
Global Preimplantation Genetic Testing Market is anticipated to grow with an elevated CAGR of around 10% over the forecast period (2021-2027). Preimplantation genetic testing is done before the implantation is achieved and helps in diagnosing various genetic defects present within the embryos. This genetic testing assists in analyzing the genetic profile of embryos which aids in avoiding selective pregnancy termination.
The preimplantation genetic testing market has been growing on account of various factors including a rising awareness among couples regarding the advancements in diagnostics coupled with a large number of neonatal deaths because of complications during childbirth. Further, the growing prevalence of various congenital genetic diseases such as Edwards syndrome, common pediatric respiratory disorders, down’s syndrome, among others is also one of the prominent factors contributing to the growth of the market. For instance, nearly 3 million deaths are attributed to pediatric pneumonia across the globe each year, according to the data published by the United Nations Children's Fund (UNICEF) in November 2018. This abnormality was exclusively seen in couples with hereditary disorders due to which there has been an increased demand for early diagnosis which in turn is boosting the preimplantation genetic testing market.
Additionally, With rapid technological advancement and rising awareness among the consumers, many of the industry players are focused on launching new products in the market due to which the market is witnessing an uptick all over the globe. For example, in October 2019, PerkinElmer launched the PG-Seq Rapid Non-Invasive Preimplantation Genetic Testing for Aneuploidy kit, which tests spent embryo culture media for chromosomal abnormalities during in vitro treatment.
Thermo Fisher Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina, Inc., The Cooper Companies Inc., Bioarray S.L., Natera Inc., Quest Diagnostics Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche AG, are some of the prominent players operating in the preimplantation genetic testing market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with preimplantation genetic testing products.
Insights Presented in the Report
"Amongst Product & Services, reagents & consumables segment holds the major share”
Based on product & services, the preimplantation genetic testing market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment accounted for the largest market share in 2020 it is estimated that it will exhibit the highest CAGR during the forecast owing to the growing applications of specific technologies such as NGS, FISH, etc. for the diagnosis of genetic disorders.
"Amongst Technology, next-generation sequencing segment holds the major share”
Based on technology, the preimplantation genetic testing market is segmented into next-generation sequencing, polymerase chain reaction, fluorescent in-situ hybridization, comparative genomic hybridization, and single nucleotide polymorphism. The next-generation sequencing segment occupied the substantial share of the preimplantation genetic testing market in 2020 and it is expected to grow considerably in the upcoming years as it is essential for successful embryo transfer and achieving pregnancy, thus plummeting the time and cost. Also, the growing adoption of automation and reduction in human errors are some of the factors driving the growth of the segment.
"Amongst Procedure Type, preimplantation genetic screening segment holds the major share”
Based on procedure type, the market is fragmented into preimplantation genetic screening and preimplantation genetic diagnosis. In 2020, the preimplantation genetic screening segment grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period owing to the declining fertility rate due to rising maternal age. Additionally, the benefits offered by preimplantation genetic screening are also one prominent reason contributing to the growth of this segment. Some of them include an increased likelihood of healthy pregnancy, a better rate of implantation, decreased risks of miscarriage and reduced cycle time of IVF, etc.
"Amongst Application, aneuploidy segment holds the major share”
Based on application, the market is fragmented into aneuploidy, structural chromosomal abnormalities, single-gene disorders, x-linked disorders, HLA typing, and gender identification. In 2020, the aneuploidy segment grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period. The growth of this segment is attributed to the rising incidences of aneuploidy due to the increasing maternal age. However, the HLA Typing segment is expected to grow at the highest CAGR over the projected timeframe due to the growing number of patients with damaged bone marrow or defective immune systems.
"North America represents one of the largest markets of the preimplantation genetic testing market”
For a better understanding of the market dynamics of the preimplantation genetic testing market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America constitutes a major market for the preimplantation genetic testing market industry and generated revenue of USD XX Million in 2020 owing to the growing healthcare expenditure and an increase in infertility cases in the region.
Reasons to buy this report:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook